- Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors. Herben, V.M., Schellens, J.H., Swart, M., Gruia, G., Vernillet, L., Beijnen, J.H., ten Bokkel Huinink, W.W. J. Clin. Oncol. (1999)